Venetoclax plus azacitidine treatment regimen

Venetoclax/Venetoclax (Venetoclax) and azacitidine (Azacitidine) combination therapy is an innovative treatment method that is widely used in hematological malignancies such as chronic lymphocytic leukemia (CLL) and high-risk acute myeloid leukemia (AML). This combination therapy is designed to work synergistically through venetoclax's BCL-2 inhibition and azacitidine's DNA methylation inhibition to more effectively inhibit cancer cell growth, induce apoptosis, and improve patient treatment response and survival rate.

Venetoclax/VenetoclaxAs a BCL-2 inhibitor, BCL-2 is a key anti-apoptotic protein that can inhibit the apoptotic process. In some tumors, BCL-2 is overexpressed, allowing cancer cells to escape the normal apoptosis mechanism, leading to their abnormal survival and proliferation. Venetoclax/Venetoclax’s mechanism of action is to specifically bind and inhibit BCL-2 protein, blocking its inhibitory effect on apoptosis. In this way, venetoclax causes cancerous cells to undergo programmed cell death, thereby reducing the number of abnormal cells and controlling tumor growth and spread. Azacitidine is a cell cycle-specific DNA methylation inhibitor. By causing DNA demethylation in cancer cells, it interferes with the growth and division of cancer cells, ultimately leading to cell apoptosis. The purpose of combining the two is to achieve a more comprehensive and effective intervention in tumor cells through the targeting of different pathways.

The advantage of this combined treatment plan is that it intervenes in multiple links simultaneously, effectively improving the comprehensive efficacy of the treatment. First of all, Venetoclax/Venetoclax destroys the resistance mechanism of cancer cells to apoptosis by inhibiting BCL-2 protein and increases the sensitivity of cancer cells to apoptotic signals. Secondly, azacitidine affects gene expression by adjusting DNA methylation levels, further promoting the apoptosis of cancer cells. The synergistic effect of these two drugs makes the therapeutic effects complementary to each other and improves the patient's efficacy.

The choice of this combination treatment usually depends on the patient's specific circumstances, including the type of disease, severity of illness, and the patient's health status, among other factors. Clinical research and practice have proven that the combination treatment of venetoclax and azacitidine shows significant efficacy in some patients with refractory or relapsed hematological malignancies.

However, as with any treatment, this combination may come with some side effects. For example, blood-related adverse reactions such as anemia, thrombocytopenia, infection, and other common discomforts associated with drug treatment may occur. Therefore, during treatment, patients need to be closely monitored and maintain close communication with their doctors to respond to potential adverse reactions in a timely manner.

Taken together, the combination of venetoclax/venetoclax and azacitidine represents a cutting-edge, personalized approach to the treatment of hematological malignancies. By fully understanding the mechanism of action of these two drugs and their synergistic effects when used in combination, doctors can better formulate precise and effective treatment plans for patients, providing patients with better treatment results and survival prognosis.

Venetoclax/Venetoclax has been launched in China and has been included in medical insurance, and patients can purchase it domestically. Specifications: 100mg*14tablets and the price is around 5,000yuan. Please consult the local hospital pharmacy for specific prices. There are original drugs and generic drugs abroad. The Turkish version of Venetoclax/Venetoclaxoriginal drug on the market overseas, specification: 100mg*112 tablets, costs about 10,000 per box. Foreign generic drugs are relatively cheaper. For example, the generic drugs sold in Laos and Bangladesh are priced at about more than 4,000 yuan for 100mg*120 tablets. The ingredients of original drugs and generic drugs are basically the same.